首页|期刊导航|中药新药与临床药理|基于PTEN/AKT/mTOR通路探讨补心泻肺方改善慢性心力衰竭小鼠心肌纤维化的作用机制

基于PTEN/AKT/mTOR通路探讨补心泻肺方改善慢性心力衰竭小鼠心肌纤维化的作用机制OA

Mechanism of Buxin Xiefei Formula in Alleviating Myocardial Fibrosis in Mice with Chronic Heart Failure via the PTEN/AKT/mTOR Pathway

中文摘要英文摘要

目的 基于PTEN/AKT/mTOR通路探讨补心泻肺方改善慢性心力衰竭(CHF)小鼠心肌纤维化的作用及分子机制.方法 采用腹腔注射盐酸异丙肾上腺素(5 mg·kg-1,每日 2 次,共 14 d)建立C57/BL6J小鼠慢性心力衰竭模型,将小鼠随机分为对照组、模型组及补心泻肺方低(2.9 g·kg-1)、中(5.8 g·kg-1)、高(11.6 g·kg-1)剂量组和培哚普利组(0.41 mg·kg-1).补心泻肺方各剂量组和培哚普利组灌胃相应药物,对照组和模型组灌胃等体积生理盐水,共 4 周.采用小动物心脏彩超检测左心室射血分数(LVEF)、左室短轴缩短率(LVFS)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD)水平;HE染色法观察小鼠心脏组织病理变化;Masson染色观察心肌纤维化变化;qRT-PCR法检测心脏组织中 α-SMA、Collagen Ⅰ和 Collagen Ⅲ mRNA 表达水平;Western Blot 法检测心脏组织 α-SMA、Collagen Ⅰ、Collagen Ⅲ、PTEN、p-AKT、p-mTOR、AKT、mTOR蛋白表达水平.结果 (1)与对照组比较,模型组小鼠的LVEF和LVFS值明显降低(P<0.01),LVEDD、LVESD、LVEDV和LVESV值明显升高(P<0.01);HE染色显示模型组小鼠的心肌细胞边缘界限不清晰,细胞肿胀,局部炎症细胞浸润;Masson染色显示心肌纤维沉积;心脏组织α-SMA,Collagen Ⅰ和Collagen Ⅲ的mRNA和蛋白表达水平均明显升高(P<0.01);PTEN蛋白表达水平明显升高(P<0.01),p-AKT/AKT、p-mTOR/mTOR比值明显降低(P<0.01).(2)与模型组比较,补心泻肺方低、中、高剂量组小鼠的LVEF、LVFS值明显升高(P<0.01),LVEDD、LVESD、LVEDV和LVESV值明显降低(P<0.01);心脏组织病理损伤和纤维化明显改善;心脏组织α-SMA、Collagen Ⅰ和Collagen Ⅲ的mRNA和蛋白表达水平均明显降低(P<0.01);PTEN蛋白表达水平明显降低(P<0.01),p-AKT/AKT和p-mTOR/mTOR比值明显升高(P<0.01).结论 补心泻肺方能够有效改善慢性心力衰竭小鼠心功能,抑制心室重构,其作用机制可能与调节PTEN/AKT/mTOR信号通路介导的心肌纤维化有关.

Objective To investigate the effect and molecular mechanism of Buxin Xiefei Formula(BXXF)in improving myocardial fibrosis in mice with chronic heart failure(CHF)based on the PTEN/AKT/mTOR pathway.Methods A CHF model was established in C57/BL6J mice by intraperitoneal injection of isoproterenol hydrochloride(5 mg·kg-1,twice daily for 14 days).The mice were randomly divided into a control group,model group,low-dose BXXF(2.9 g·kg-1),medium-dose BXXF(5.8 g·kg-1),and high-dose BXXF group(11.6 g·kg-1),and a perindopril group(0.41 mg·kg-1).The BXXF groups and perindopril group were administered the corresponding drugs by gavage,while the control and model groups received an equal volume of saline for 4 weeks.Cardiac function was assessed using small-animal echocardiography to measure left ventricular ejection fraction(LVEF),left ventricular fractional shortening(LVFS),left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular end-diastolic diameter(LVEDD),and left ventricular end-systolic diameter(LVESD).Pathological changes in cardiac tissue were observed by HE staining,while myocardial fibrosis was evaluated by Masson staining.The mRNA expression levels of α-SMA,Collagen Ⅰ,and Collagen Ⅲ in cardiac tissue were detected by qRT-PCR,and the protein expression levels of α-SMA,Collagen Ⅰ,Collagen Ⅲ,PTEN,p-AKT,p-mTOR,AKT,and mTOR were measured by Western Blot.Results(1)Compared with the control group,the model group showed significantly decreased LVEF and LVFS values(P<0.01)and significantly increased LVEDD,LVESD,LVEDV,and LVESV values(P<0.01).HE staining revealed unclear myocardial cell boundaries,cell swelling,and local inflammatory cell infiltration in the model group.Masson staining indicated myocardial collagen deposition.The mRNA and protein expression levels of α-SMA,Collagen Ⅰ,and Collagen Ⅲ in cardiac tissue were significantly increased(P<0.01).PTEN protein expression was significantly elevated(P<0.01),while the p-AKT/AKT and p-mTOR/mTOR ratios were significantly decreased(P<0.01).(2)Compared with the model group,the low-,medium-,and high-dose BXXF groups exhibited significantly increased LVEF and LVFS(P<0.01)and significantly decreased LVEDD,LVESD,LVEDV,and LVESV(P<0.01).Pathological damage and fibrosis in cardiac tissue were markedly improved.The mRNA and protein expression levels of α-SMA,Collagen Ⅰ,and Collagen Ⅲ were significantly decreased(P<0.01).PTEN protein expression was significantly reduced(P<0.01),while the p-AKT/AKT and p-mTOR/mTOR ratios were significantly increased(P<0.01).Conclusion BXXF effectively improves cardiac function and inhibits ventricular remodeling in mice with CHF,and its mechanism may be associated with the regulation of PTEN/AKT/mTOR signaling pathway-mediated myocardial fibrosis.

黄培红;孙丹淳;马惠旋;王远平;靳利利

广东省第二中医院,广东 广州 510095广州中医药大学第五临床医学院,广东 广州 510095广东省第二中医院,广东 广州 510095广州中医药大学第五临床医学院,广东 广州 510095广东省第二中医院,广东 广州 510095

补心泻肺方慢性心力衰竭心肌纤维化心室重构PTEN/AKT/mTOR通路小鼠

Buxin Xiefei Formulachronic heart failuremyocardial fibrosisventricular remodelingPTEN/AKT/mTOR pathwaymice

《中药新药与临床药理》 2026 (1)

52-60,9

国家自然科学基金-青年科学基金项目(82405259)广东省医学科学技术研究基金项目(A2024041)广东省第二中医院科研创新基金项目-基础与应用基础研究青年启航项目(SEZYY2023A10)广东省第二中医院科研创新基金项目(SEZYY2023B18).

10.19378/j.issn.1003-9783.2026.01.006

评论